Who Generates Higher Gross Profit? BioMarin Pharmaceutical Inc. or MorphoSys AG

BioMarin's Gross Profit Dominance Over MorphoSys

__timestampBioMarin Pharmaceutical Inc.MorphoSys AG
Wednesday, January 1, 201462127600063900978
Thursday, January 1, 2015737887000106145897
Friday, January 1, 201690723400049646515
Sunday, January 1, 2017107186000066757840
Monday, January 1, 2018117594800074645876
Tuesday, January 1, 2019134458200059670105
Wednesday, January 1, 20201336183000318524319
Friday, January 1, 20211375760000147400000
Saturday, January 1, 20221612370000229647003
Sunday, January 1, 20231842161000179923313
Monday, January 1, 20242273680000
Loading chart...

Unleashing insights

BioMarin vs. MorphoSys: A Decade of Gross Profit Comparison

In the competitive landscape of the pharmaceutical industry, BioMarin Pharmaceutical Inc. and MorphoSys AG have been key players. Over the past decade, BioMarin has consistently outperformed MorphoSys in terms of gross profit. From 2014 to 2023, BioMarin's gross profit surged by nearly 200%, peaking at approximately $1.84 billion in 2023. In contrast, MorphoSys AG, despite a notable spike in 2020, has seen a more modest growth, with its highest gross profit reaching around $318 million in the same year.

This trend highlights BioMarin's robust market strategy and product portfolio, which have enabled it to maintain a significant lead. Meanwhile, MorphoSys's fluctuating figures suggest a more volatile market presence. As the pharmaceutical sector continues to evolve, these insights provide a glimpse into the financial health and strategic direction of these two industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025